Taliglucerase alfa for the treatment of Gaucher's disease

Drugs of Today

Volumn 48, Issue 8, 2012, Pages 525-532

  Haddley, Kate ^a  

^a NONE

Author keywords

Glucocerebrosidase; Enzyme replacement therapy; Gaucher's disease; Polypeptides; Taliglucerase

Indexed keywords

DRUG ANTIBODY; GLUCOSYLCERAMIDASE; GLUCOSYLCERAMIDE; IMIGLUCERASE; TALIGLUCERASE ALFA; VELAGLUCERASE ALFA;

ANAPHYLAXIS; ARTHRALGIA; ARTICLE; BACKACHE; BLOOD PRESSURE; CHROMOSOME 1Q; DISEASE SEVERITY; DRUG ACTIVITY; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; ENZYME REPLACEMENT; FATIGUE; FLUSHING; FRAMESHIFT MUTATION; GAUCHER DISEASE; GENE DELETION; GENE INSERTION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC RECOMBINATION; GENOTYPE; GROUPS BY AGE; HEADACHE; HEMATOLOGIC DISEASE; HUMAN; INFANCY; INFLUENZA; KIDNEY INFECTION; LIMB PAIN; LIVER HYPERTROPHY; MACROPHAGE; MULTICENTER STUDY (TOPIC); NEUROLOGIC DISEASE; NONHUMAN; PHARYNGITIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PHENOTYPE; POINT MUTATION; PROGNOSIS; PROTEIN FUNCTION; QUALITY OF LIFE; RHINOPHARYNGITIS; SIDE EFFECT; SKELETON MALFORMATION; SKIN REDNESS; SPLENOMEGALY; SPLICING DEFECT; THORAX PAIN; TREATMENT OUTCOME; URINARY TRACT INFECTION; URTICARIA; WEAKNESS;

ADULT; AGE FACTORS; ANIMALS; CHILD; CLINICAL TRIALS AS TOPIC; GAUCHER DISEASE; GLUCOSYLCERAMIDASE; HUMANS; PROGNOSIS; SEVERITY OF ILLNESS INDEX;

EID: 84866447640     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2012.48.8.1844808     Document Type: Article

References (52)

1. Cox, T.M. and Schofield, J.P. Gaucher's disease: clinical features and natural history. Baillieres Clin Haematol 1997, 10(4): 657-89. (Pubitemid 28022202)
2. Morales, L.E. Gaucher's disease: a review . Ann Pharmacother 1996, 30(4): 381-8. (Pubitemid 26111075)
3. Beutler, E., Nguyen, N.J., Henneberger, M.W. et al. Gaucher disease: gene frequencies in the Ashkenazi Jewish population. Am J Hum Genet 1993, 52(1): 85-8. (Pubitemid 23059051)
4. Meikle, P.J., Hopwood, J.J., Clague, A.E., Carey, W.F. Prevalence of lysosomal storage disorders. JAMA 1999, 281(3): 249-54. (Pubitemid 29058114)
5. Beutler, E. Gaucher disease. Adv Genet 1995, 32: 17-49.
6. Gaucher, P. De l'épithelioma primitif de la rate, hypertrophie idiopathique de la rate sans leukemie . Paris, France: University of Paris, 1882. [Thesis].
7. Cox, T.M. Gaucher disease: clinical profile and therapeutic developments. Biologics 2010, 4: 299-313.
8. Beutler, E., Grabowski, G.A. Gaucher disease. In: Scriver, C.R. Beaudet, A.L. Sly, W.S. Valle, D. Kinzler Vogelstein, Childs (Eds.). The Online Metabolic and Molecular Bases of Inherited Disease. The McGraw-Hill Companies, New York, NY, 2006, pp. 3635-68.
9. Stowens, D.W., Teitelbaum, S.L., Kahn, A.J., Barranger, J.A. Skeletal complications of Gaucher disease. Medicine (Baltimore) 1985, 64(5): 310-22. (Pubitemid 16224046)
10. Aerts, J.M., Donker-Koopman, W.E., Koot, M., Barranger, J.A., Tager, J.M., Schram A.W. Deficient activity of glucocere-brosidase in urine from patients with type 1 Gaucher disease. Clin Chim Acta 1986, 158(2): 155-63.
11. Aerts, J.M. and Hollak, C.E. Plasma and metabolic abnormalities in Gaucher's disease. Baillieres Clin Haematol 1997, 10(4): 691-709. (Pubitemid 28022203)
12. Barak, V., Acker, M., Nisman, B. et al. Cytokines in Gaucher's disease. Eur Cytokine Netw 1999, 10(2): 205-10. (Pubitemid 29332776)
13. Beutler, E., Kuhl, W. The diagnosis of the adult type of Gaucher's disease and its carrier state by demonstration of deficiency of beta-glucosidase activity in peripheral blood leukocytes. J Lab Clin Med 1970, 76(5): 747-55.
14. Beutler, E., Kuhl, W. Detection of the defect of Gaucher's disease and its carrier state in peripheral-blood leucocytes. Lancet 1970, 1(7647): 612-3.
15. Van Weely, S., Van Leeuwen, M.B., Jansen, I.D., et al. Clinical phenotype of Gaucher disease in relation to properties of mutant glucocerebrosidase in cultured fibroblasts. Biochim Biophys Acta 1991, 1096(4): 301-11.
16. Beutler, E., Gelbart, T., Scott, C.R. Hematologically important mutations: Gaucher disease. Blood Cell Mol Dis 2005, 35: 355-64. (Pubitemid 41627801)
17. Hruska, K.S., LaMarca, M.E., Scott, C.R., Sidransky, E. Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA). Human Mutat 2008, 29: 567-83. (Pubitemid 351614580)
18. Sibille, A., Eng, C.M., Kim, S.J., Pastores, G., Grabowski, G.A. Phenotype/genotype correlations in Gaucher disease type I: clinical and therapeutic implications. Am J Hum Genet 1993, 52(6): 1094-101. (Pubitemid 23311350)
19. Hollak, C., Maas, M., Akkerman, E., et al. Quantitative chemical shift imaging is a sensitive tool for the evaluation of bone marrow responses to individualized doses of enzyme supplementation therapy in type 1 Gaucher disease. Blood Cells Mol Dis 2001, 27: 1005-12. (Pubitemid 34163969)
20. Goker-Alpan O. Therapeutic approaches to bone pathology in Gaucher disease: Past, present and future. Mol Genet Metab 2011, 104(4): 438-47.
21. Campbell, T.N., Choy, F.Y. Gaucher disease and the synucleinopathies: refining the relationship. Orphanet J Rare Dis 2012, 7: 12.
22. Choy, F.Y., Zhang, W., Shi, H.P. et al. Gaucher disease among Chinese patients: review on genotype/phenotype correlation from 29 patients and identification of novel and rare alleles. Blood Cell Mol Dis 2007, 38(3): 287-93. (Pubitemid 46533937)
23. Mistry, P.K. Genotype/phenotype correlations in Gaucher's disease. Lancet 2003, 346(8981): 982-3.
24. Bubbar, V., Las Heras, F., Amato, D., Pritzker, K.P.H., Gross, A.E. Total hip replacement in Gaucher's disease. Effects of enzyme replacement therapy. J Bone Joint Surg Br 2009, 91(12): 1623-7.
25. Elstein, D., Hollak, C., Aerts, J.M. et al. Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease. J Inherit Metab Dis 2004, 27(6): 757-66. (Pubitemid 39433603)
26. Brumshtein, B., Greenblatt, H.M., Butters, T.D. et al. Crystal structures of complexes of N-butyl- and N-nonyl-deoxynojirimycin bound to acid-beta-glucosidase: Insights into the mechanism of chemical chaperone action in Gaucher disease. J Biol Chem 2007, 282(39): 29052-58. (Pubitemid 47606022)
27. Barton, N.W., Brady, R.O., Dambrosia, J.M. et al. Replacement therapy for inherited enzyme deficiency - macrophage-targeted glucocerebrosidase for Gaucher's disease. N Engl J Med 1991, 324(21): 1464-70.
28. Damiano, A.M., Pastores, G.M., Ware, J.E. Jr. The health-related quality of life of adults with Gaucher's disease receiving enzyme replacement therapy: results from a retrospective study. Qual Life Res 1998, 7(5): 373-86. (Pubitemid 28343447)
29. Elstein, D., Zimran, A. Review of the safety and efficacy of imiglucerase treatment of Gaucher disease. Biologics 2009, 3: 407-17.
30. Weinreb, N., Taylor, J., Cox, T., Yee, J., Vom Dahl, S. A benchmark analysis of the achievement of therapeutic goals for type 1 Gaucher disease patients treated with imiglucerase. Am J Hematol 2008, 83(12): 890-5.
31. Wenstrup, R.J., Kacena, K.A., Kaplan, P. et al. Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease. J Bone Miner Res 2007, 22(1): 119-26. (Pubitemid 46032604)
32. Aerts, J.M., Yasothan, M., Kirkpatrick, P. Velglucerase alfa. Nat Rev Drug Discov 2010, 9(11): 837-8.
33. Elstein, D., Cohn, G.M., Wang, N. et al. Early achievement and maintenance of the therapeutic goals using velaglucerase alfa in type 1 Gaucher disease. Blood Cells Mol Dis 2011, 46(1): 119-23.
34. Shaaltiel, Y., Bartfeld, D., Hashmueli, S. et al. Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher's disease using a plant cell system. Plant Biotechnol J 2007, 5(5): 579-90. (Pubitemid 47196361)
35. Traynor, K. Taliglucerase alfa approved for Gaucher disease. Am J Health Syst Pharm 2012, 69(12): 1009.
36. Aviezer, D., Almon-Brill, E., Shaaltiel, Y. et al. A plantderived recombinant human glucocerebrosidae enzyme - A preclinical and phase I investigation. PLoS ONE 2009, 4(3): e4792.
37. Almon-Brill, E., Chertkoff, R., Maas, M. et al. Novel enzyme replacement therapy for Gaucher disease: Clinical program with plant cell expressed recombinant glucocerebrosidase (prGCD) - taliglucerase alfa. 60th Annu Meet Am Soc Hum Genet (ASHG) (Nov 2-6, Washington, D.C.) 2010, Abst 3065/W.
38. A phase I, non-randomized, open label, single dose-escalation safety study of recombinant human glucocerebrosidase (prGCD) in healthy volunteers (NCT00258778). ClinicalTrials.gov Web site. Accessed June 13, 2012.
39. Aviezer, D., Almon-Brill, E., Shaaltiel, Y. et al. Novel enzyme replacement therapy for Gaucher disease: Ongoing phase III clinical trials with recombinant human glucocerebrosidase expressed in plant cells. 41st Eur Hum Genet Conf (May 23-26, Vienna) 2009, Abst.
40. Aviezer, D., Almon-Brill, E., Shaaltiel, Y. et al. Novel enzyme replacement therapy for Gaucher's disease: Ongoing phase III clinical trial with recombinant human glucocerebrosidase expressed in plant cells. World Symp Lysosomal Dis Netw (Feb 18-20, San Diego) 2009, Abst 8.
41. Zimran, A., Almon-Brill, E., Chertkoff, R. et al. Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease. Blood 2011, 118(22): 5767-73.
42. A phase III, multicenter, randomized, double-blind trial to assess the safety and efficacy of two parallel dose groups of plant cell expressed recombinant human glucocerebrosidase (prGCD) in patients with Gaucher disease (NCT00376168). ClinicalTrials.gov Web site. Accessed June 13, 2012.
43. Zimran, A., Petakov, M., Terreros Munoz, E. et al. Novel ERT for Gaucher's disease: Clinical program with plant cell expressed recombinant glucocerebrosidase - Taliglucerase alfa. Annu Clin Genet Meet (March 16-20, Vancouver) 2011, Abst.
44. Pastores, G., Fernhoff, P., Szer, J. et al. Plant cell expressed recombinant glucocerebrosidase - taliglucerase alfa as therapy for Gaucher disease in patients previously treated with imiglucerase. Mol Gen Metab 2012, 105: S50.
45. A phase 3 multicenter, open-label, switchover trial to assess the safety and efficacy of plant cell expressed recombinant human glucocerebrosidase in patients with Gaucher disease treated with imiglucerase (NCT00712348). ClinicalTrials.gov Web site. Accessed June 13, 2012.
46. A multicenter, double-blind, extension trial of two parallel dose groups of plant cell expressed recombinant human glucocerebrosidase (prGCD) in patients with Gaucher disease (NCT00705939). ClinicalTrials.gov Web site. Accessed June 13, 2012.
47. Van Dussen, L., Hollak, C., Zimran, A., et al. Long term bone marrow responses, as measured by quantitative chemical shift imaging (QCSI) MRI, following treatment with taliglucerase alfa in patients with type 1 Gaucher disease. Mol Genet Metab 2012, 105: S62.
48. An open-label expanded access trial of plant cell expressed recombinant human glucocerebrosidase (prGCD) in patients with Gaucher disease who require enzyme replacement therapy (NCT00962260). ClinicalTrials.gov Web site. Accessed June 13, 2012.
49. A multicenter, double-blind, randomized safety and efficacy study of two dose levels of taliglucerase alfa in pediatric subjects with Gaucher disease (NCT01132690). ClinicalTrials.gov Web site. Accessed June 13, 2012.
50. A multicenter extension study of taliglucerase alfa in pediatric subjects with Gaucher disease (NCT01411228). ClinicalTrials.gov Web site. Accessed June 13, 2012.
51. A multicenter extension study of taliglucerase alfa in adult subjects with Gaucher disease (NCT01422187). ClinicalTrials.gov Web site. Accessed June 13, 2012.
52. Stirnemann, J., Kaminsky, P., Peronne, C. et al. Effects of treatment with taliglucerase in 29 Gaucher disease patients, 6 month follow-up from French ATU program. Annu Symp Soc Study Inborn Errors Metab (SSIEM) (Aug 30-Sept 2, Geneva) 2011, Abst O-053.